Analyst Conference Summaries

Biotechnology Investor Aids

Alnylam Pharmaceuticals
ALNY

conference date: February 15, 2024 @ 5:30 AM Pacific Time

Alnylam: Potential Is In Line With Current Valuation by William Meyers [October 7, 2021 Seeking Alpha]

Alnylam's RNA Therapies Make It A Buy by William Meyers [November 28, 2020 Seeking Alpha]

Alnylam as a Strategic Investment by William Meyers [February 21, 2019 Seeking Alpha]

Alnylam: Fully Priced, But A Future Star by William Meyers [August 21, 2018 Seeking Alpha]

Analyst Conference Notes by William P. Meyers
2023
Alnylam
Q1 2023
Alnylam
Q2 2023
Alnylam
Q3 2023
Alnylam
Q4 2023
May 4, 2023 Aug. 3, 2023 Nov. 2, 2023 Feb. 15, 2024
2022
Alnylam
Q1 2022
Alnylam
Q2 2022
Alnylam
Q3 2022
Alnylam
Q4 2022
April 28, 2022 July 28, 2022 Oct. 27, 2022 Feb. 23, 2023
2021
Alnylam
Q1 2021
Alnylam
Q2 2021
Alnylam
Q3 2021
Alnylam
Q4 2021
April 29, 2021 August 3, 2021 Oct. 28, 2021 Feb. 10, 2022
2020
Alnylam
Q1 2020
Alnylam
Q2 2020
Alnylam
Q3 2020
Alnylam
Q4 2020
May 6, 2020 Aug. 6, 2020 Nov. 5, 2020 Feb. 11, 2021
2019
Alnylam
Q1 2019
Alnylam
Q2 2019
Alnylam
Q3 2019
Alnylam
Q4 2019
May 1, 2019 August 6, 2019 Oct. 31, 2019 Feb. 6, 2020
2018
Alnylam
Q4 2018
May 3, 2018
August 2, 2018
Nov. 7, 2018
Feb. 7, 2019
2017
May 5, 2017
August 9, 2017
Nov. 7, 2017
Feb. 8, 2018
2016
05/02/2016
08/04/2016
11/02/2016
02/08/2017
2015
05/07/2014
08/06/2015
11/09/2015
02/11/2016

Alnylam Readouts Offer Catalysts for 2017-2018 [June 24, 2016 Seeking Alpha]
Why Alnylam Should Be a Big Mover in 2016 [December 8, 2015 at Seeking Alpha]

Is Alnylam in 2020 Worth $9 Billion Now? [April 28, 2015 at Seeking Alpha]

Alnylam Pharmaceuticals (ALNY) is a clinical-stage developer of RNAi based therapies.

Alnylam web site

I sold my remaining ALNY stock on October 9, 2017. I may buy again if the stock price or developments make it attractive, by my standards, again.

 

Search

More Analyst Conference Pages:

 AGEN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BLUE
 BMY
 CDTX
 CLDX
 FATE
 GILD
 GLYC
 ILMN
 INCY
 INO
 IONS
 MCHP
 MRNA
 REGN
 RNA
 SAGE
 SANA
 SGEN
 SYRS
 TSVT
 VRTX
 VSTM
 WBA

       

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2023 William P. Meyers